Partnership to provide monitoring for cancer and CVD risks

Cancer screening provider Check4Cancer has partnered with Alula Technologies to create a digitally enabled platform for assessing and managing risk for cancer and cardiovascular disease (CVD) risks.

Combining Check4Cancer’s MyCancerRisk© and VivaScore® from Alula Technologies, the platform provides a comprehensive solution for assessing, monitoring, and understanding both cancer and cardiovascular disease risks – the top two causes of global insurance claims in 2023.

The MyCancerRisk© platform identifies employees at higher risk for six common cancers using an online, tailored questionnaire. Those at higher risk are directed to risk reduction and cancer screening.

Check4Cancer CEO and chief medical officer Professor Gordon Wishart (pictured) said: ‘By partnering with Alula, we can jointly tackle the top two causes of global claims by raising awareness of the risks and symptoms of both cancer and CVD and, by promoting targeted prevention strategies.’

CVD is a growing challenge for health systems, with almost 8 million people living with the disease in the UK.

Alula Health managing director Simon Spurr said: ‘Evidence shows that preventative health checks, combined with behavioural changes, can significantly reduce [CVD] prevalence. Our innovative VivaScore solution leverages advanced data analytics to provide users with a clear understanding of their health risks, empowering them to make impactful behavioural changes through an engaging and user-friendly experience. We are excited to partner with Check4Cancer to address two of the largest drivers of insurance claims, delivering better health outcomes together.’